Denali Therapeutics
DNLI
210 hedge funds and large institutions have $2.51B invested in Denali Therapeutics in 2024 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 76 increasing their positions, 69 reducing their positions, and 34 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 69
4.62% more ownership
Funds ownership: 83.34% → 87.96% (+4.6%)
6% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 34
2% more capital invested
Capital invested by funds: $2.47B → $2.51B (+$43.7M)
2% more call options, than puts
Call options by funds: $2.5M | Put options by funds: $2.46M
0% more funds holding
Funds holding: 209 → 210 (+1)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$59M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$28.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$24.4M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$21.1M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$18.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$29M |
| 2 |
Temasek Holdings
Singapore
|
-$22.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$18.4M |
| 4 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$18M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.8M |
DNLI Hedge Fund Activity: Q1 2024 in Review
210 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q1 2024, worth a combined $2.51B — up 1.8% from $2.47B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new DNLI positions and 34 closed out — a net gain of 2 holders — while 76 added to existing stakes and 69 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $59M. The largest seller was Federated Hermes, exiting entirely with an estimated $29M sold.
- 210 institutional investors held Denali Therapeutics (DNLI) as of Q1 2024, up from 209 in Q4 2023.
- Funds reported $2.51B of Denali Therapeutics stock for Q1 2024, up 1.8% quarter-over-quarter.
- 36 funds opened new Denali Therapeutics positions in Q1 2024 and 34 closed out, a net change of +2 holders.
- The largest Denali Therapeutics buyer in Q1 2024 was Capital Research Global Investors, an estimated $59M added.
- The largest Denali Therapeutics seller in Q1 2024 was Federated Hermes, an estimated $29M sold.
Based on aggregated 13F filings for Q1 2024.